Bedrijfsoverzicht
Generation Bio Co. is a biotechnology firm dedicated to discovering, developing, and commercializing redosable therapeutics designed to reprogram T cells in vivo, thereby reducing or eliminating the production and persistence of autoreactive T cells. This specific operational focus places the entity squarely within the Healthcare sector, specifically the Biotechnology industry, where companies typically engage in high-risk, high-reward research and development to advance medical treatments. The company currently maintains a market capitalization of $35.98M and employs 115 individuals to support its specialized scientific initiatives. While the annual revenue stands at $15.27M, the combination of a market cap significantly exceeding annual revenues and a relatively small workforce indicates an early-stage enterprise that relies heavily on capital markets for funding rather than generating substantial operating cash flow to sustain operations.
Financiële gezondheid
The company reported a revenue of $15.27M over the trailing twelve months, yet it posted a net income of -$62,627,000 and an EBITDA of -$76,380,000, revealing a cost structure where expenses vastly outweigh revenue generation. This substantial gap between the $15.27M in revenue and the -$62.6M net loss suggests that the company is burning significant capital on research, development, and commercialization efforts typical of biotechnology firms that have not yet achieved profitability. The free cash flow stands at -$40,196,752, which indicates that the company is currently using cash reserves to fund its operations and growth initiatives rather than returning capital to shareholders or paying down debt. Analysis of the margins shows a gross margin of -212.2%, an operating margin of -2020.0%, and a profit margin of 0.0%, all of which reflect the aggressive spending patterns and lack of traditional profitability found in pre-commercial biotech entities. On the balance sheet, the company holds $89.62M in cash against $26.10M in debt, resulting in a debt-to-equity ratio of 51.61, which suggests a leveraged position relative to equity but one that is underpinned by a significant cash buffer. The current ratio is 4.44, indicating a strong short-term liquidity position where current assets are more than four times current liabilities, providing ample room to meet short-term obligations. Furthermore, the return on equity is -80.8% and the return on assets is -27.4%, metrics that reveal that management has not yet generated positive returns on the capital invested in the company's assets or equity base.
Waarderingsbeoordeling
The valuation metrics present a complex picture, with a trailing P/E ratio of N/A and a forward P/E of -3.99, implying that the company is not currently profitable and that any forward-looking P/E calculation is distorted by negative earnings expectations. The price-to-book ratio is 0.71, indicating that the market values the company at approximately 71% of its book value, which often suggests the market perceives the firm's intangible assets or future growth potential as not fully reflected in its current asset base. Alternative valuation metrics such as the price-to-sales ratio of 2.36 and an EV/EBITDA of 0.36 suggest that investors are pricing the stock based on revenue multiples rather than earnings, a common practice for biotechnology companies that are still in their development phase. The stock has traded between a 52-week high of $7.60 and a 52-week low of $3.00, meaning the current valuation sits within a range that reflects significant volatility but remains below the recent peak. The beta value of 2.01 indicates that the stock's price volatility is twice as high as that of the broader market, exposing investors to substantial price swings relative to general market movements.
Growth & Income
The company experienced a revenue growth of -78.9% year-over-year, while earnings growth is marked as N/A, highlighting a situation where the company is contracting in terms of top-line revenue without any profitable earnings to track. Since the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute any earnings to shareholders, and the zero payout ratio is unsustainable only in the traditional sense because there are no positive earnings to distribute. Consequently, the company reinvests all available capital and cash reserves into research, development, and commercialization efforts to advance its redosable therapeutics pipeline rather than providing income to investors. The overall growth and income profile is characterized by significant revenue contraction, negative returns on capital, and a total reliance on external financing or cash reserves to fund future operational needs without current income generation.